Prescribing patterns for the use of antithrombotics in the management of atrial fibrillation in Zimbabwe

Central African Journal of Medicine

Volumn 45, Issue 11, 1999, Pages 287-290

  Bhagat, K ^a   Tisocki, K ^b  

^a UNIV OF ZIMBABWE MEDICAL SCHOOL   (Zimbabwe)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOLYTIC AGENT; WARFARIN;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CROSS-SECTIONAL STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MALE; MIDDLE AGED; RISK FACTOR; ZIMBABWE;

ADULT; ASPIRIN; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CROSS-SECTIONAL STUDIES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; WARFARIN; ZIMBABWE;

EID: 0033223397     PISSN: 00089176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22:983-8.
2. Petersen P, Godtfredsen J, Boysen G, Paul SS, Krantz A, Stein M. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet 1989;1:175-9.
3. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation 1991;84:527-39.
4. The Boston Area Anticoagulation Trial for the Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11.
5. Connolly SJ, Laupacis A, Gent M, Paxton G, Neil ZW, for the CAFA study co-investigators. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991;18:349-55.
6. Ezekowitz MD, Bridgers S, James KE, Clarkson K, McAllister M, for Veterans Affairs Stroke Prevention in Nonrheumatic atrial fibrillation investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-12.
7. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet 1994;343:687-91.
8. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 1993;42:1255-62.
9. Barnett HJM, Eliasziw M, Meldrum BE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995;332:238-48.
10. Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest 1995;108:352S-9S.
11. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994;154:1449-57.
12. Hakim JG, Manyemba J. Cardiac disease distribution among patients referred for echocardiography in Harare, Zimbabwe. Cent Afr J Med. 1998;44:140-44.
13. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med 1996;156:2537-41.
14. Laupacis A, Albers G, Dunn M, Bell P, Sellers JJ. Antithrombotic therapy in atrial fibrillation. Chest 1992;102(suppl):426S-33S.
15. McNamara CA, Burket MW, Brewster PS, Dinesh B, Gorlin JJ. Comparison of thrombolytic therapy for acute myocardial infarction in rural and urban settings. Am J Med 1987;82:1095-1101.
16. Eitel DR, Walton SL, Guerci AD, Hertz JS, Howard DB, Jacobs P. Out-of-hospital cardiac arrest: a six year experience in a suburban-rural system. Ann Emerg Med 1988;17:808-12.
17. Stults KR, Brown DD, Kerber RE. Efficacy of an automated external defibrillator in the management of out-of-hospital cardiac arrest: validation of the diagnostic algorithm and initial clinical experience in a rural environment. Circulation 1986;73:701-9.